AU2017360941A1 - Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 - Google Patents

Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 Download PDF

Info

Publication number
AU2017360941A1
AU2017360941A1 AU2017360941A AU2017360941A AU2017360941A1 AU 2017360941 A1 AU2017360941 A1 AU 2017360941A1 AU 2017360941 A AU2017360941 A AU 2017360941A AU 2017360941 A AU2017360941 A AU 2017360941A AU 2017360941 A1 AU2017360941 A1 AU 2017360941A1
Authority
AU
Australia
Prior art keywords
fluorophenyl
carboxamide
indole
dioxidotetrahydrothiophen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017360941A
Other languages
English (en)
Inventor
Fa-Xiang Ding
Thomas H. Graham
Jinlong Jiang
Dong-Ming Shen
Clare TUDGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2017360941A1 publication Critical patent/AU2017360941A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017360941A 2016-11-18 2017-11-13 Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 Abandoned AU2017360941A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424106P 2016-11-18 2016-11-18
US62/424,106 2016-11-18
PCT/US2017/061226 WO2018093698A1 (en) 2016-11-18 2017-11-13 Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

Publications (1)

Publication Number Publication Date
AU2017360941A1 true AU2017360941A1 (en) 2019-05-16

Family

ID=62146797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017360941A Abandoned AU2017360941A1 (en) 2016-11-18 2017-11-13 Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Country Status (12)

Country Link
US (1) US10947222B2 (enExample)
EP (1) EP3541376B1 (enExample)
JP (1) JP2020500192A (enExample)
KR (1) KR20190085035A (enExample)
CN (1) CN109963561A (enExample)
AU (1) AU2017360941A1 (enExample)
BR (1) BR112019009731A2 (enExample)
CA (1) CA3043206A1 (enExample)
MA (1) MA46859A (enExample)
MX (1) MX2019005679A (enExample)
RU (1) RU2019117958A (enExample)
WO (1) WO2018093698A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021236405A1 (en) 2020-05-18 2021-11-25 Merck Sharp & Dohme Corp. Novel diacylglyceride o-acyltransferase 2 inhibitors
KR20230107802A (ko) * 2020-09-30 2023-07-18 에프엘2022-001, 인코포레이티드 Hsd17b13 억제제 및 이의 용도
PE20240217A1 (es) * 2020-10-08 2024-02-16 Merck Sharp And Dohme Llc Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
JP7604636B2 (ja) * 2020-10-08 2024-12-23 メルク・シャープ・アンド・ドーム・エルエルシー 新規なジアシルグリセリドｏ－アシルトランスフェラーゼ２阻害剤としてのベンゾイミダゾロン誘導体の製造
CN120500483A (zh) 2022-12-02 2025-08-15 默沙东有限责任公司 作为新型二酰基甘油o-酰基转移酶2抑制剂的稠合唑衍生物的制备
WO2024151519A2 (en) * 2023-01-09 2024-07-18 University Of Florida Research Foundatin, Incorporated Pparg modulators

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ES2210728T3 (es) 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
HK1042496B (zh) 1998-09-09 2006-01-27 症变治疗公司 新的果糖1，6-二磷酸酶的杂芳族抑制剂
DE60128475T2 (de) 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
PE20030547A1 (es) * 2001-09-24 2003-08-18 Bayer Corp Derivados de imidazol para el tratamiento de la obesidad
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
DK1537078T3 (da) 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
JP2007504285A (ja) 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7759365B2 (en) 2005-04-30 2010-07-20 Boehringer Ingelheim International Gmbh Piperidine-substituted indoles
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
WO2007084435A2 (en) 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
AU2008205642B2 (en) 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives
CN101743616B (zh) 2007-06-28 2012-02-22 株式会社半导体能源研究所 半导体装置的制造方法
EP2170883A1 (en) 2007-06-28 2010-04-07 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
WO2009058298A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
ES2553412T3 (es) 2007-10-31 2015-12-09 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
AU2009309019B2 (en) 2008-10-31 2014-11-13 Merck Sharp & Dohme Llc P2X3, receptor antagonists for treatment of pain
AR075858A1 (es) 2009-03-18 2011-05-04 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
WO2010111060A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
WO2010111059A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
EP2410857B1 (en) 2009-03-23 2014-01-29 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US8927576B2 (en) 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
WO2012150784A2 (ko) 2011-05-03 2012-11-08 한국생명공학연구원 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
JP6279600B2 (ja) * 2012-11-23 2018-02-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
WO2016036633A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188731B1 (en) 2014-09-05 2019-04-03 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
CN107635975B (zh) 2015-05-20 2020-07-24 伊莱利利公司 Dgat2抑制剂

Also Published As

Publication number Publication date
MX2019005679A (es) 2019-08-14
MA46859A (fr) 2019-09-25
CA3043206A1 (en) 2018-05-24
WO2018093698A1 (en) 2018-05-24
EP3541376A4 (en) 2020-05-20
EP3541376B1 (en) 2023-04-19
US20190276443A1 (en) 2019-09-12
CN109963561A (zh) 2019-07-02
BR112019009731A2 (pt) 2019-08-13
KR20190085035A (ko) 2019-07-17
RU2019117958A3 (enExample) 2021-03-04
US10947222B2 (en) 2021-03-16
RU2019117958A (ru) 2020-12-18
EP3541376A1 (en) 2019-09-25
JP2020500192A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
EP3188732B1 (en) Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188730B1 (en) Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188731B1 (en) Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3541376B1 (en) Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
AU2017360939B2 (en) Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US10239863B2 (en) Factor XIa inhibitors
US9868727B2 (en) Factor XIa inhibitors
WO2015047973A1 (en) FACTOR XIa INHIBITORS
KR20230157981A (ko) 인자 xiia 저해제
WO2013048916A1 (en) Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US20150274664A1 (en) Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2025231011A1 (en) Heteroarylindole inhibitors of apol-1

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted